Готові списки джерел за темами / Compound Kushen Injection

Добірка наукової літератури з теми "Compound Kushen Injection"

Автор: Grafiati

Опубліковано: 10 грудня 2022

Оновлено: 28 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Статті в журналах
Дисертації
Тези доповідей конференцій
Звіти організацій

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Compound Kushen Injection".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Compound Kushen Injection"

Huang, Zhihong, and Ping Wei. "Compound Kushen Injection for gastric cancer." Medicine 98, no. 45 (November 2019): e17927. http://dx.doi.org/10.1097/md.0000000000017927.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Yang, Xinwei, Xiyun Zhao, and Xiaoxia Wang. "Compound kushen injection for multiple myeloma." Medicine 98, no. 50 (December 2019): e18257. http://dx.doi.org/10.1097/md.0000000000018257.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Guo, Yu-ming, Yi-xue Huang, Hong-hui Shen, Xiu-xiu Sang, Xiao Ma, Yan-ling Zhao, and Xiao-he Xiao. "Efficacy of Compound Kushen Injection in Relieving Cancer-Related Pain: A Systematic Review and Meta-Analysis." Evidence-Based Complementary and Alternative Medicine 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/840742.

Повний текст джерела

Анотація:

Despite widespread popular use of complementary and alternative medicine (CAM) therapies, a rigorous evidence based on the efficacy of compound kushen injection (CKI) for cancer-related pain is lacking. In this study, we evaluated the efficacy and safety of compound kushen injection and provided information for current or future research and clinical application. Sixteen trials were identified with a total of 1564 patients. The total pain relief rate of CKI plus chemotherapy is better than chemotherapy except for colorectal cancer. The treatment groups achieved a reduction in the incidences of leukopenia and gastrointestinal, hepatic, and renal functional lesion. However, there is paucity of multi-institutional RCTs evaluating compound kushen injection for cancer pain with adequate power, duration, and sham control. The quantity and quality of RCTs are lower so that we still have to boost the research level through scientific design and normative report.

Стилі APA, Harvard, Vancouver, ISO та ін.

Duan, Yuntao, Weijian Liang, Junming Hou, and Dezhen Yang. "Research Progress on the Antitumor Mechanism of Compound Kushen Injection." Proceedings of Anticancer Research 5, no. 5 (September 24, 2021): 4–6. http://dx.doi.org/10.26689/par.v5i5.2511.

Повний текст джерела

Анотація:

Compound Kushen Injection (CKI), as a clinical traditional Chinese medicine preparation, has prominent antitumor effect but with several side effects. A large number of studies have shown that CKI plays an antitumor role by regulating tumor cell proliferation, inducing tumor cell differentiation and apoptosis, inhibiting tumor cell invasion and metastasis, reducing tumor angiogenesis, regulating the immunity, and so on. Clinically, CKI is widely used to treat various tumors, where it is often combined with surgery, chemotherapy, radiotherapy, targeted therapy, and other antitumor treatments. This article reviews the antitumor mechanism of CKI and the progress of its clinical application in order to provide a theoretical basis for further clinical application.

Стилі APA, Harvard, Vancouver, ISO та ін.

Wang, Wei, Rong-li You, Wen-jie Qin, Li-na Hai, Ming-jing Fang, Guo-hua Huang, Rui-xia Kang, et al. "Anti-tumor activities of active ingredients in Compound Kushen Injection." Acta Pharmacologica Sinica 36, no. 6 (May 18, 2015): 676–79. http://dx.doi.org/10.1038/aps.2015.24.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Meng, Ziqi, Xinkui Liu, Jiarui Wu, Wei Zhou, Kaihuan Wang, Zhiwei Jing, Shuyu Liu, Mengwei Ni, and Xiaomeng Zhang. "Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology." Evidence-Based Complementary and Alternative Medicine 2019 (May 28, 2019): 1–15. http://dx.doi.org/10.1155/2019/4637839.

Повний текст джерела

Анотація:

Background. Compound Kushen Injection (CKI) is a Chinese patent drug that shows good efficacy in treating lung cancer (LC). However, its underlying mechanisms need to be further clarified.Methods. In this study, we adopted a network pharmacology method to gather compounds, predict targets, construct networks, and analyze biological functions and pathways. Moreover, molecular docking simulation was employed to assess the binding potential of selected target-compound pairs.Results. Four networks were established, including the compound-putative target network, protein-protein interaction (PPI) network of LC targets, compound-LC target network, and herb-compound-target-pathway network. Network analysis showed that 8 targets (CHRNA3, DRD2, PRKCA, CDK1, CDK2, CHRNA5, MMP1, and MMP9) may be the therapeutic targets of CKI in LC. In addition, molecular docking simulation indicated that CHRNA3, DRD2, PRKCA, CDK1, CDK2, MMP1, and MMP9 had good binding activity with the corresponding compounds. Furthermore, enrichment analysis indicated that CKI might exert a therapeutic role in LC by regulating some important pathways, namely, pathways in cancer, proteoglycans in cancer, PI3K-Akt signaling pathway, non-small-cell lung cancer, and small cell lung cancer.Conclusions. This study validated and predicted the mechanism of CKI in treating LC. Additionally, this study provides a good foundation for further experimental studies and promotes the reasonable application of CKI in the clinical treatment of LC.

Стилі APA, Harvard, Vancouver, ISO та ін.

Yang, Yang, Yu Lu, Tianduo Pei, Bao Guo, Jingquan Li, Hui Wang, and Qian Ba. "Compound kushen injection in cancer treatments: Efficacy, active ingredients, and mechanisms." Pharmacological Research - Modern Chinese Medicine 3 (June 2022): 100108. http://dx.doi.org/10.1016/j.prmcm.2022.100108.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Jiang, Hongqiang, Honglei Tu, Yanxia Jin, Xianjin Wu, Ziyi Luo, Yanling Chen, Dongdong Zhang, et al. "Therapeutic Effect of a Traditional Chinese Medicine Compound Mixture Compound Kushen Injection in Treating Multiple Myeloma." Blood 136, Supplement 1 (November 5, 2020): 31–32. http://dx.doi.org/10.1182/blood-2020-141929.

Повний текст джерела

Анотація:

Abstract Background: Multiple myeloma (MM) is a hematology malignant disease originated from B-cell line and still incurable. Compound Kushen Injection (CKI) as a Traditional Chinese Medicines are promising agents in our previous research for treating cancer. The effect of CKI on multiple myeloma was still unknown. Methods: In vitro experiment, flow cytometry was used to evaluate effect of CKI on multiple myeloma cells. Optofluidic chip was applied to detect effect at single-cell level. And in vivo RPMI-8226 GFP+ B-NSG mouse model was built to assess the role of CKI in multiple myeloma treatment. Results: CKI inhibited MM cells proliferation of and increased its apoptosis rate. And the cell cycle of MM cells was also arrested by CKI treatment. In contrast, CKI has few toxic effects on mesenchymal stem cells (MSCs) and MC3T3 cells. At the single-cell level, MM cells was died in time and dose dependent manner. Transcriptome find that the expression of MYC and TERT in CKI-treated RPMI-8226 cells was significantly down-regulated and confirmed by qRT-PCR and Western blot. Overexpression of TERT can partly reverse the inhibition effect of CKI on RPMI-8226 cells. B-NSG mouse was injected with GFP+ RPMI-8226 cells through caudal vein, and the disease was partially alleviated by decreased tumor burden in the CKI-treated group. Furthermore, it is surprising that in animal models with myeloma bone disease, the bone mass was higher in CKI treatment group than control. Conclusions: CKI inhibits MM cells through the MYC/TERT signaling pathway and improve the quality of life of MM mouse. Our findings provide preclinical evidence to show that CKI could be a promising candidate in human MM therapy. Disclosures No relevant conflicts of interest to declare.

Стилі APA, Harvard, Vancouver, ISO та ін.

Liang, Sixian, Yin Li, Xiangguo Zhang, Yugan Guo, and Suming Pan. "Molecular Evidence of Compound Kushen Injection Against Lung Cancer: A Network Pharmacology-Based Investigation from Western Medicine to Traditional Medicine." Anti-Cancer Agents in Medicinal Chemistry 21, no. 15 (September 8, 2021): 2012–22. http://dx.doi.org/10.2174/1871520621666210126090632.

Повний текст джерела

Анотація:

Background: Compound Kushen Injection (CKI) is used clinically for relieving cancer pain and treating various solid tumors, particularly lung cancer. However, the underlying mechanisms of CKI in lung cancer remain to be further elucidated. Objective: This study aimed to obtain evidence regarding the potential efficacy of the active compounds and therapeutic targets of CKI at a molecular level by using Network Pharmacology (NP), which is an emerging technique for dealing with complex systems, such as those of herbal medicine. Methods: The chemical and predicted target information of CKI was obtained from databases and computational prediction, respectively; lung-cancer drugs and their corresponding targets were retrieved from Drugbank and Drugcentral. The online tool, STRING, was used to gather target–pathway interactions for establishing a target–(pathway)–target network to identify the target group that was most relevant to cancer. Based on this module, a protein-protein interaction network was established for identifying the potential therapeutic targets and the potential active ingredients. Results: CKI might affect lung cancer drug targets or their neighbor nodes to trigger anti-cancer effects. The compounds that were predicted to bind to the potential therapeutic targets were recommended as potential active ingredients of CKI, which included naringenin from Baituling, and kurarinone and isoxanthohumol from Kushen. Conclusion: This NP-based study might provide insights into understanding CKI from the perspective of modern science with reference to approved Western medicine for lung cancer. Moreover, network-based methods could also be further used with distinct advantages in dealing with complex information and systems of medicine.

Стилі APA, Harvard, Vancouver, ISO та ін.

Qu, Zhipeng, Jian Cui, Yuka Harata-Lee, Thazin Nwe Aung, Qianjin Feng, Joy M. Raison, Robert Daniel Kortschak, and David L. Adelson. "Identification of candidate anti-cancer molecular mechanisms of Compound Kushen Injection using functional genomics." Oncotarget 7, no. 40 (September 1, 2016): 66003–19. http://dx.doi.org/10.18632/oncotarget.11788.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Compound Kushen Injection"

Aung, Thazin Nwe. "Molecular Mechanisms of Natural Compounds : Compound Kushen Injection (CKI) in Cancer." Thesis, 2019. http://hdl.handle.net/2440/120399.

Повний текст джерела

Анотація:

Chemotherapy is a treatment that uses cytotoxic drugs to kill rapidly dividing cancer cells. There are many anti-cancer chemotherapeutic drugs used alone or in combination with others to kill cancerous cells, and some of these, are of plant origin. Naturally occurring compounds, such as Taxol, are used in chemotherapy and have very specific, unique, molecular targets. However, according to the World Health Organization (Ekor, 2014), approximately eighty percent of the world’s population depends on natural compounds from traditional medicine and these compounds are widely used in complementary medicine as anti-cancer drugs (Foster et al., 2000). Traditional Chinese medicine (TCM) uses treatments that contain multiple natural compounds, a number of which have been claimed to be of therapeutic benefit to cancer sufferers (Chung et al., 2015). Some TCM preparations have shown anti-cancer, anti-migratory and anti-metastatic properties in laboratory settings (Wang et al., 2009;Pan et al., 2011;Qu et al., 2016). Research suggests that TCM natural compound mixtures might synergistically trigger therapeutic benefits through the action of multiple components affecting multiple regulatory signaling targets (Wang et al., 2008). Compound Kushen injection (CKI) is a TCM anticancer agent which has been approved by the Chinese State Food and Drug Administration to treat solid tumors in combination with chemotherapy drugs in clinics for pain relief, cancer metastasis and enhancement of the immune system since 1995, and is used to treat approximately 30,000 patients daily. Although a large body of evidence has suggested CKI has anti-cancer properties (Xu et al., 2011;Gao et al., 2018) the anti-cancer mechanisms attributable to specific compounds within the mixture remain unknown. CKI contains multiple alkaloid and flavonoid compounds and the main bioactive compounds such as matrine and oxymatrine have shown to affect cancer cells in the lab. However, other medicinal herbs containing these two compounds as main components have demonstrated patient toxicity. It is therefore important to better understand the effects of CKI, particularly with respect the contributions of individual compounds within the mixture. In this thesis, I describe a multi-disciplinary approach including analytical chemistry, cellular assays and transcriptome analysis to explore the effects of several major compounds present in CKI. Through the application of a subtractive fractionation method that removed individual compounds one, two or three at a time, I have been able to map these compounds and their interactions to specific pathways based on altered gene expression profiles. This has illuminated the roles of several major compounds of CKI, that on their own, have no, or minimal, activity in our bioassay. This approach has enabled us to identify the interactions between compounds in a mixture as shown by the response of cancer cell cultures. Using a systems biology approach along with cellular migration and invasion assays, I have mapped the activity of related proteins and pathways which may contribute to the migrastatic activity of CKI. Altogether, this thesis presents an initial characterization of the underlying mechanistic changes induced by CKI. First, by comparing differentially expressed genes across treatment combinations generated using our subtractive fractionation approach, I identified specific candidate pathways that were altered by the removal of compounds from the mixture. Second, by using transcriptome data of a breast cancer cell line, the effects of CKI on candidate anti-migratory pathways for six different cancer cell lines were assessed. These experiments identified specific candidate target pathways through which CKI might act. These approaches can be used to understand the roles and interactions of individual compounds from any complex natural compound mixture whose biological activity cannot be associated with purified compounds.
Thesis (Ph.D.) -- University of Adelaide, School of Biological Sciences, 2019

Стилі APA, Harvard, Vancouver, ISO та ін.

Shen, Hanyuan. "Bioinformatics in Traditional Chinese Medicine (TCM): Potential anti-cancer mechanisms of Compound Kushen Injection (CKI)." Thesis, 2019. http://hdl.handle.net/2440/120755.

Повний текст джерела

Анотація:

With thousands of years of clinical practice, Traditional Chinese Medicine (TCM) is an enormous resource for both the pharmaceutical industry and daily health care. However, the wide popularization and application of TCM are hindered by the ambiguous explanation of mechanisms with ancient Chinese concepts. In addition, modern pharmacologic methods based on the interaction between single compound drug and target are inadequate to deal with the complex mixtures for TCM formulas which usually contain plant secondary metabolites from several or even dozens of herbs. New high-throughput technologies and bioinformatics methods can provide systematic and holistic ways to understand biological processes. Applying these methods to TCM research, we can clarify complex biological processes that result from hundreds or thousands of molecular interactions between components in TCM and targets in the organism. Therefore, the purpose of my project is to use models for the application of high-throughput sequencing technologies and bioinformatics methods in order to understand the molecular basis of TCM that involve drug-drug and compound-compound interactions. My model TCM, Compound Kushen Injection (CKI) is an anticancer agent clinically used in China since 1995. It’s commonly used as an adjuvant medicine in the treatment of carcinomas for pain relief, activation of innate immune response and reducing side effects of chemo or radiotherapy. Extracted from two herbs, CKI contains multiple alkaloids and flavonoids, which have been shown to be bioactive in previous studies. However, with the exception of several purified, well characterised compounds, the underlying mechanisms of action for CKI are still unclear. In this thesis, I first applied transcriptome analysis and bioinformatics methods as part of a pipeline to investigate interactions between CKI and chemotherapy drugs. With this pipeline, the mechanisms for the opposing effects of CKI combined with doxorubicin compared to 5-fluorouracil (5-Fu) were determined, and potential interactions between CKI and chemotherapeutic anticancer agents were revealed. These results are closely related to the clinical usage of CKI and may help refine its clinical application. As my second approach, I applied transcriptome analysis to investigate the role of the two plant extracts that make up CKI in order to determine which plant extract contains the primary bioactivity and to identify how the two plant extracts interact to generate the combined effects from CKI. Altogether, this thesis presents approaches for the application of transcriptome analysis in order to identify the molecular mechanisms perturbed by CKI. I have successfully applied systems-biology based approaches to analyse herb-drug interactions and herbal compatibility and demonstrated these methods are valuable additions to TCM research. In addition, my results have indicated that high-throughput sequencing technologies and bioinformatics methods are powerful tools for linking TCM with modern pharmacologic methods.
Thesis (Ph.D.) -- University of Adelaide, School of Biological Sciences, 2019

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Compound Kushen Injection"

Su, Yifan, Dehui Li, Huanfang Fan, and Chunxia Sun. "Compound Kushen Injection combined with Chemotherapy in Advanced Gastric Cancer." In IMIP 2020: 2020 2nd International Conference on Intelligent Medicine and Image Processing. New York, NY, USA: ACM, 2020. http://dx.doi.org/10.1145/3399637.3399653.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Xu, Ting, Patrea Rhea, Tara Conway, Mihai Gagea, Lirong Wu, Zhongxing Liao, and Peiying Yang. "Abstract 6549: Preventive effect of compound Kushen injection in radiation induced lung pneumonitis." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-6549.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Compound Kushen Injection"

Huang, Jinsheng, Teng Fan, Yuming Rong, Xujia Li, Qi Jiang, Jun Kan, Huijuan Qiu, Qi Quan, Bei Guo, and Guifang Guo. Efficacy of Aidi injection combined with chemotherapy, radiotherapyor chemoradiotherapy for unresectable esophageal cancer treatment: A meta-analysis and systematic review of 29 randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0020.

Повний текст джерела

Анотація:

Review question / Objective: In recent years, many articles have shown the significant clinical effects of traditional Chinese medicine for esophageal cancer (EC) treatment. These studies involved Chinese medicine injection, decoction, acupuncture, and moxibustion. Chinese medicine injections, including Aidi injection (Aidi) (Z52020236, China food and Drug Administration; composed of 0.15 g/ml cantharis, 5 g/ml ginseng, 10 g/ml Astragalus and 15 g/ml Eleutherococcus senticosus at a ratio of 0.03:1:2:3. The three plant names have been checked with http://www.theplantlist.org 2022/6/4), Shenqifuzheng injection, Kanglaite injection, compound Kushen injection, and Kangai injection, are widely used to treat cancer in clinical practice because of their efficacy and convenience. Aidi combined with standard treatment, including chemotherapy, radiotherapy, or chemoradiotherapy (CR) (Aidi-based combination therapy), showed significant efficacy in the treatment of unresectable EC. However, existing studies are limited to small sample sizes, and the efficacy of Aidi in the treatment of unresectable EC has not been confirmed in large-scale phase III clinical trials. Therefore, it is important to derive more convincing results by analyzing all the reported data. Herein, we conducted a literature search for all randomized controlled trials (RCTs) that applied Aidi-based combination therapy in unresectable EC treatment, and a meta-analysis was performed to evaluate the efficacy of Aidi-based combination therapy in unresectable EC treatment.

Стилі APA, Harvard, Vancouver, ISO та ін.

Mao, Qiyuan, Lanchun Liu, Xueqian Wang, Huiling Zhou, Xue Li, Ruijuan Cai, Surui Yuan, and Hongsheng Lin. Compound Kushen injection combined with chemotherapy for patients with non-Hodgkin lymphoma: A protocol for systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2021. http://dx.doi.org/10.37766/inplasy2021.2.0063.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Zhou, Tong, Shuo Wang, Lanxin Zhang, Yuerong Gui, Jun Dong, Dandan Wang, and Bingjie Fan. Efficacy and Safety of Compound Kushen Injection Combined With Oxaliplatin-Based Chemotherapy in the Treatment of Advanced Colorectal Cancer: a Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2021. http://dx.doi.org/10.37766/inplasy2021.9.0059.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!